Journal of Cancer Immunology

Original Research Open Access

Mycosis Fungoides Derived Exosomes: Mediators of Tumor Survival and Immune Suppression

Coral Arkin , Emmilia Hodak , Jamal Knaneh , Haneen Khoury , Batia Gorovitz-Haris , Iris Amitay-Laish , Hadas Prag-Naveh , Lilach Moyal

Mycosis fungoides (MF) is the most common cutaneous T cell lymphoma (CTCL). Tumor-derived exosomes are endosome-derived extra-cellular-vesicles secreted by cancer cells to create tumor favorable niche. We previously demonstrated that MF-exosomes deliver a significant load of miR-155 and miR-1246 into recipient cells and increase their motility. 

Commentary Open Access

Predicting Durable Anti-tumor Immune Responses after Cancer Vaccines 

John B. Liao , Mary L. Disis

Recent reports and ongoing clinical trials demonstrate potential roles for cancer vaccine therapy in a number of malignancies. Adaptive cellular immune responses are required for protective immunity when vaccines are used against infectious diseases. For therapeutic cancer vaccines used to treat established tumors, elaboration of durable T cell mediated responses are also understood to be necessary for efficacy. Immune responses measured in peripheral blood lymphocytes correlate with clinical outcomes. 

Commentary Open Access

Cristae Architecture as a Metabolic Checkpoint in Effector T Cells — Implications for Cancer Immunity

Prakash Jeysankar , Sonal Srikanth , Beibei Wu , Yousang Gwack

Effector T cells rely on tightly coordinated metabolic and epigenetic programs to sustain immune function. Emerging evidence highlights a central role for mitochondria in integrating these programs through nutrient utilization and regulation of metabolite flux. The electron transport chain (ETC), localized to the inner mitochondrial membrane, directs cellular metabolism toward oxidative phosphorylation.

Original Research Open Access

TACSTD2 Expression Associates with CD4⁺ Memory T Cell Infiltration and Epithelial-Hormone Programs in Glioblastoma: An In silico Analysis

Tahreem Fatima

Glioblastoma (GBM) is characterized by profound immunosuppression and poor response to immunotherapy. Sex biased incidence and outcomes suggest that immune programs may be differentially regulated in males and females, but the molecular substrates of this divergence remain incompletely defined. TACSTD2 (TROP2), an epithelial lineage marker and therapeutic target in multiple solid tumors, is normally silent in the brain yet becomes aberrantly reactivated in a subset of GBM via promoter CpG hypomethylation with sex modulated prognostic effects. 

Commentary Open Access

Novel High-Dose Chemotherapy for Multiply Relapsed and Refractory Germ-Cell Tumors

Yago Nieto

Germ-cell tumors (GCT) are among the most curable solid malignancies, with approximately 70% of patients with advanced disease cured by frontline cisplatin-based standard-dose chemotherapy (SDC), with or without surgery [1]. However, outcomes are worse for patients whose tumors relapse or have refractory disease.